| Drug ID: | Drug191 |
|---|---|
| Drug Name: | Hydrocortisone acetate |
| CID: | 5744 |
| DrugBank ID: | DB14539 |
| Modality: | Small Molecule |
| Groups: | NULL |
| US Approved: | YES |
| Other Approved: | YES |
| Identifier: | NCT02837432, , NCT04148261, , NCT04615962, , NCT03358082, , NCT02671058, , NCT02689856, , NCT00801957, , NCT00610142, , NCT00980135, , NCT01691209, , NCT01228110 |
| Molecular Formula: | C23H32O6 |
| Molecular Weight: | 404.5 g/mol |
| Isomeric SMILES: | CC(=O)OCC(=O)[C@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)O)C)O |
| Synonyms: | hydrocortisone acetate; 50-03-3; Cortisol 21-acetate; Cortell; Cortifoam; Cortef acetate; Cortisol acetate; Lanacort; Hydrocortisat; Hydrocortistab |
| Phase 0: | 2 |
| Phase 1: | 7 |
| Phase 2: | 11 |
| Phase 3: | 7 |
| Phase 4: | 0 |
| Description: | NULL |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt1335 | 5744 | Hydrocortisone Acetate | 2908 | NR3C1 | Homo sapiens (human) | Agonist | |
| dt1336 | 5744 | Hydrocortisone Acetate | 538 | ATP7A | Mus musculus (house mouse) | 2346371 | ATP7A mutant form results in increased susceptibility to hydrocortisone acetate |
| dt1337 | 5744 | Hydrocortisone Acetate | 2908 | NR3C1 | Homo sapiens (human) | Glucocorticoid receptor agonist | |
| dt1338 | 5744 | Hydrocortisone Acetate | 4780 | NFE2L2 | Homo sapiens (human) | None | |
| dt1339 | 5744 | Hydrocortisone Acetate | 301 | ANXA1 | Homo sapiens (human) | Agonist | |
| dt1340 | 5744 | Hydrocortisone Acetate | 3291 | HSD11B2 | Homo sapiens (human) | 22273746 | None |
| dt1341 | 5744 | Hydrocortisone Acetate | 3283 | HSD3B1 | Homo sapiens (human) | 25526675 | None |
| dt1342 | 5744 | Hydrocortisone Acetate | 1576 | CYP3A4 | Homo sapiens (human) | 1302569 | Substrate|Inducer |
| dt1343 | 5744 | Hydrocortisone Acetate | 1577 | CYP3A5 | Homo sapiens (human) | Substrate |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| No data available | |||||||
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| No data available | |||||
No related literature
You can run management commands to establish drug-literature associations